New-onset maternal gestational hypertension and risk of retinopathy of prematurity.
OBJECTIVE
To evaluate associations between conditions of maternal new-onset gestational hypertension (mHTN) and the features imparting risk of severe retinopathy of prematurity (ROP) in preterm infants.


METHODS
Hospital databases and charts of all preterm inborn infants at the University of North Carolina from 1996 to 2007 were retrospectively reviewed. The presence or absence of mHTN (e.g., pre-eclampsia) and infant factors (birthweight, gestational age, erythropoietin use, and zone and stage of ROP) were analyzed for independence of association.


RESULTS
Of the 5143 infants, 323 had ROP and 76 had mothers with mHTN. Infants with ROP were more likely to have mothers with mHTN and to be younger and smaller at birth. At initial examination, more infants of mothers with mHTN had vascularization into the lower zones than did infants of mothers without mHTN (P < 0.001). However, at the examination in which the most severe ROP was present, there was no association between mHTN and ROP stage (P = 0.2342). Analysis of stage and zone together showed that infants born to mothers with mHTN were more likely to have ROP at initial examination, after adjustment for gestational age, but not for birth weight. The use of erythropoietin was not associated with ROP zone or stage, even after adjustment for maternal condition, infant birth weight, or gestational age.


CONCLUSIONS
Although larger avascular areas or higher severity scores were associated with mHTN after adjustment for gestational age at initial examination, no associations were found between mHTN and ROP severity score at the examination when ROP was most severe. There were no associations between ROP severity and treatment with erythropoietin.
Zayed
Mohamed A
MA
Department of Ophthalmology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Uppal
Abhineet
A
Hartnett
M Elizabeth
ME
D000751:Anemia, Neonatal / Q000517:prevention & control; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000008:administration & dosage; D005260:Female; D005865:Gestational Age; D006801:Humans; D046110:Hypertension, Pregnancy-Induced / Q000175:diagnosis / Q000209:etiology*; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D011247:Pregnancy; D011994:Recombinant Proteins; D012178:Retinopathy of Prematurity / Q000145:classification / Q000175:diagnosis / Q000209:etiology*; D012189:Retrospective Studies; D012307:Risk Factors
D011994:Recombinant Proteins; D004921:Erythropoietin
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004863
16856062
N Engl J Med. 2004 Feb 12;350(7):672-83
14764923
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004865
16856063
Reprod Biol Endocrinol. 2009 Jul 14;7:70
19602262
Exp Eye Res. 2006 Sep;83(3):473-83
16750526
Semin Perinatol. 2000 Feb;24(1):24-8
10709854
Am J Obstet Gynecol. 2007 Oct;197(4):418.e1-5
17904985
J Matern Fetal Neonatal Med. 2008 Jan;21(1):9-23
18175241
Arch Ophthalmol. 2003 Dec;121(12):1684-94
14662586
N Engl J Med. 2003 Jul 31;349(5):427-34
12890841
J Clin Endocrinol Metab. 2009 Jul;94(7):2252-4
19584199
Ophthalmologica. 2000;214(2):131-5
10720918
J AAPOS. 2006 Apr;10(2):143-9
16678749
J Clin Invest. 2003 Mar;111(5):649-58
12618519
J AAPOS. 2008 Jun;12(3):233-8
18589385
Arch Ophthalmol. 1994 Jul;112(7):903-12
8031269
Pediatrics. 2009 Apr;123(4):e638-45
19289449
Clin Sci (Lond). 1998 Aug;95(2):115-28
9680492
J Perinatol. 2009 Oct;29(10):680-4
19609308
J Clin Invest. 2008 Feb;118(2):526-33
18219389
Prenat Diagn. 2008 Sep;28(9):852-8
18702104
Ann Acad Med Singap. 2005 Mar;34(2):169-78
15827664
Pediatrics. 2006 Feb;117(2):572-6
16452383
Lancet. 2000 Oct 7;356(9237):1260-5
11072961
Lancet. 1997 Jul 5;350(9070):12-4
9217713
Am J Perinatol. 1990 Jan;7(1):23-5
2294905
Am J Obstet Gynecol. 2007 Apr;196(4):396.e1-7; discussion 396.e7
17403433
Br J Ophthalmol. 1984 Oct;68(10):690-7
6548150